HAE stock forecast, quote, news & analysis
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces... Show more
Why Haemonetics (HAE) Stock Is Up +15% in the Last 30 Days
Key Takeaways
- Haemonetics (HAE) shares have risen roughly 15% over the past 30 days, climbing from about $104.68 to near $120.79.
- The primary catalyst was an expanded CSL Plasma supply agreement covering Haemonetics' NexSys PCS plasma collection platform across all existing U.S. plasma centers by the end of 2027.
- Several analysts raised their price targets on HAE to as high as $140 following the disclosure, reinforcing a broadly positive view of the plasma franchise.
- The stock is up roughly 41% over the trailing three months, extending a multi-quarter recovery that began with an initial CSL agreement in August.
- Management kept fiscal 2027 guidance intact and expects to update the anticipated financial impact of the CSL deal on its November earnings call.
- For additional detail on HAE, review its Price Targets, Earnings history, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are positioning around this and other tickers.
Haemonetics (HAE) Company Overview and Market Position
Haemonetics Corporation is a global medical technology company headquartered in Boston, Massachusetts, focused on blood and plasma management. The company operates through three primary segments: Plasma, Blood Center, and Hospital. Its Plasma business includes the NexSys PCS and Persona plasma collection platform, related disposables, and donor management software; the Blood Center segment supplies automated apheresis solutions; and the Hospital segment offers interventional technologies such as vascular closure devices, hemostasis management, cell salvage, and transfusion management products.
Haemonetics' competitive strength lies in its installed base of plasma collection devices, which generate recurring disposables revenue for every donation, alongside a growing hospital portfolio. Investors follow the stock closely because plasma collection volumes and hospital procedure trends drive demand for the company's consumables-heavy business model, making its segments sensitive to both patient volumes and donor activity.
Haemonetics (HAE) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, HAE advanced approximately 15%, rising from a closing price of about $104.68 to near $120.79. The move was not linear; shares drifted lower into early October before a sharp single-day surge following the expanded CSL Plasma disclosure on October 8, and the stock subsequently consolidated in a range around the $117–$122 level.
The near-term gain extends a considerably larger advance over the trailing three months. From an early-August close of roughly $85.38, the stock has climbed approximately 41%, reflecting a sustained re-rating of the company's plasma collection franchise. The quarterly trend has been defined by two distinct catalysts rather than steady appreciation: a double-digit percentage jump in August on the initial CSL agreement, followed by a second surge in October when the rollout was expanded to all U.S. centers.
What Drove HAE Stock Price in the Last 30 Days
The dominant driver of the recent move was an October 8 SEC filing in which Haemonetics disclosed that CSL Plasma expects to adopt its NexSys PCS devices with Persona PLUS technology and related disposables across all of its existing U.S. plasma collection centers, with the rollout targeted for completion by the end of 2027. The announcement expanded the scope of a non-exclusive supply agreement first reached in August and was viewed by investors as a meaningful recurring-revenue opportunity, given CSL Plasma's position as one of the largest plasma collection networks in the country.
The disclosure triggered a wave of analyst actions. BTIG, Barrington Research, Mizuho, and BofA each raised price targets, with several moving to $140, citing the expanded rollout and Haemonetics' leadership position in plasma collection technology. Haemonetics also maintained its fiscal 2027 guidance, stating it would update the anticipated financial impact during its November earnings call. Separately, the company announced U.S. FDA approval of its PerQseal Elite vascular closure system in mid-October, expanding its interventional technologies portfolio.
What Drove HAE Stock Performance Over the Last Quarter
The broader three-month advance reflects a re-rating of Haemonetics' plasma business rather than a single isolated event. In early August, the company reported fiscal first-quarter results that beat analyst expectations, and on August 18 it announced the initial non-exclusive CSL Plasma supply agreement, which sent shares sharply higher. The October disclosure that CSL intended to transition all of its U.S. centers to Haemonetics' platform converted a preliminary agreement into a more concrete multi-year growth catalyst.
Underpinning the move, analysts framed CSL's decision as third-party validation of Haemonetics' technology, with several research notes citing potential upside to sales and adjusted earnings per share as the rollout is executed through 2027. The combination of an earnings beat, a marquee customer win, and upward price-target revisions has supported the stock's advance even as broader healthcare and medical-device sectors experienced mixed trading conditions.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a much larger universe of automated strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, trading timeframe, and performance metrics, allowing traders to compare approaches ranging from short-term momentum to longer-horizon trend following. Because the section is curated for relevance and recent performance, it can serve as a useful starting point for investors interested in exploring how algorithmic strategies are positioning across the market. Reviewing the page may help identify AI-driven approaches that align with a given trading style.
HAE Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring HAE should watch execution of the CSL Plasma rollout and the company's fiscal second-quarter results, scheduled for November 5, when management is expected to update the anticipated financial impact of the supply agreement and provide updated guidance. Consensus estimates at the time of the October disclosure projected earnings per share of about $1.29 on revenue of roughly $345 million, compared with $1.27 and $327 million in the prior-year period.
Beyond the immediate earnings catalyst, key factors include the pace of the CSL center conversion through 2027, demand trends across plasma collection and hospital procedures, and the continued integration of the Vivasure Medical acquisition into the vascular closure portfolio. Macroeconomic conditions, healthcare utilization rates, and competitive dynamics within plasma collection and interventional technologies may also influence sentiment. These factors carry both upside and downside risks, and the timing and scale of the CSL-related revenue contribution remain subject to change.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for HAE shows an upward move is likely
HAE's Aroon Indicator triggered a bullish signal on October 16, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 209 similar instances where the Aroon Indicator showed a similar pattern. In 162 of the 209 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on HAE as a result. In 50 of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for HAE just turned positive on November 04, 2026. Looking at past instances where HAE's MACD turned positive, the stock continued to rise in 26 of 40 cases over the following month. The odds of a continued upward trend are 65%.
Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where HAE advanced for three days, in 233 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HAE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
HAE broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HAE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.925) is normal, around the industry mean (4.338). P/E Ratio (61.260) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (1.676) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.668) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of blood processing systems
Industry MedicalNursingServices